Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure

Acta Pharmacologica Sinica

Volumn 35, Issue 6, 2014, Pages 792-805

  Li, Feng ^a   Zhang, Mian ^a   Xu, Dan ^a   Liu, Can ^a   Zhong, Ze Yu ^a   Jia, Ling Ling ^a   Hu, Meng Yue ^a   Yang, Yang ^a   Liu, Li ^a   Liu, Xiao Dong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 HT; Diabetes mellitus; drug drug interaction; insulin; paroxetine pravastatin; pharmacokinetics; tryptophan hydroxylase

Indexed keywords

INSULIN; PAROXETINE; PRAVASTATIN; STREPTOZOCIN; TRYPTOPHAN HYDROXYLASE; ANTIDEPRESSANT AGENT; GLUCOSE BLOOD LEVEL; HYPOCHOLESTEROLEMIC AGENT; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID BLOOD LEVEL; LIPID DIET; MALE; NONHUMAN; RAT; ANALYSIS; ANIMAL; BLOOD; CELL LINE; COMPLICATION; DEPRESSION; DIABETES COMPLICATIONS; DRUG INTERACTION; EXPERIMENTAL DIABETES MELLITUS; HYPERCHOLESTEROLEMIA; SPRAGUE DAWLEY RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; CELL LINE; DEPRESSION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DRUG INTERACTIONS; HYPERCHOLESTEROLEMIA; INSULIN; MALE; PAROXETINE; PRAVASTATIN; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 84902282789     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.24     Document Type: Article

References (48)

1. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
2. Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004; 58: 614-8.
3. Araki K, Masaki T, Katsuragi I, Kakuma T, Yoshimatsu H. Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 2008; 16: 2068-73.
4. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Preventio n Study. Circulation 2001; 103: 357-62.
5. Abe M, Toyohara T, Ishii A, Suzuki T, Noguchi N, Akiyama Y, et al. The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion throug h organic anion transporter polypeptides. Drug Metab Pharmacokinet 2010; 25: 274-82.
6. Madhu M, Abish A, Anu K, Jophin RI, Kiran AM, Vijayakumar K. Predictors of depression among patien ts with diabetes mellitus in Southern India. Asian J Psychiatr 2013; 6: 313-7.
7. Zuberi SI, Syed EU, Bhatti JA. Association of depression with treatment outcomes in type diabetes mellitus: a cross-sectional study from Karachi, Pakistan. BMC Psychiatry 2011; 11: 27.
8. Gentili P, Maldonato A, Scalabrino AM. The influence of psychological factors on the patient's management of diabetes. Critical survey of psychodynamic models on personal management of diabetes. Minerva Psichiatr 1996; 37: 83-90.
9. Lustman PJ, Griffith LS, Clouse RE, Cryer PE. Psychiatric illness in diabetes mellitus. Relationship to symptoms and glucose control. J Nerv Ment Dis 1986; 174: 736-42.
10. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 2003; 4: 7.
11. Gulseren L,Gulseren S,Hekimsoy Z,Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients, Arch Med Res, 2005, 36, 159-65.
12. Derijks HJ, Meyboom RH, Heerdink ER, De Koning FH, Janknegt R, Lindquist M, et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008; 64: 531-8.
13. Yoo n JM, Cho EG, Lee HK, Park SM. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Fam Med 2013; 34: 228-40.
14. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 2011; 90: 133-42.
15. White RW, Tatonetti NP, Shah NH, Altman RB, Horvitz E. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc 2013; 20: 404-8.
16. An L, Ravindran P P, Renukunta S, Denduluri S. Co-medication of pravastatin and paroxetine-A categorical study. J Clin Pharmacol 2013; doi: 10.1002/jcph.151.
17. Bourin M, Chue P, Guillon Y. Paroxetine: a review. CNS Drug Rev 2001; 7: 25-47.
18. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, et al. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmac okinet 1992; 17: 103-13.
19. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-25.
20. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
21. Transon C, Leemann T, Dayer P. In vitro comparative inhibiti on profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6, and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-15.
22. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39: 397-412.
23. Chen GM, Hu N, Liu L, Xie SS, Wang P, Li J, et al. Pharmacokinetics of verapamil in diab etic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica 2011; 41: 494-500.
24. Liu C, Zhang M, Hu MY, Guo HF, Li J, Yu YL, et al. Increased glucago nlike peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol 2013; 217: 185-96.
25. Kobayashi T, Matsumoto T, Kamata K. Mechanisms underlying the chronic pravastati n treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocininduced diabetic rats. Br J Pharmacol 2000; 131: 231-8.
26. Besson A, Haddjeri N, Blier P, de Montigny C. Effects of the coadministration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000; 10: 177-88.
27. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transportermediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652-62.
28. Shin JG, Kim KA, Yoon YR, Cha IJ, Kim YH, Shin SG. Rapid simple high-performance liquid chromatographic determination of paroxetine in human plasma. J Chromatogr B Biomed Sci Appl 1998; 713: 452-6.
29. Deeney JT, Branstrom R, Corkey BE, Larsson O, Berggren PO. 3H-serotonin as a marker of oscillatory insulin secretion in clonal betacells (INS-1). FEBS Lett 2007; 581: 4080-4.
30. Heimes K, Feistel B, Verspohl EJ. Impact of the 5-HT3 receptor channel system for insulin secretion and interaction of ginger extracts. Eur J Pharmacol 2009; 624: 58-65.
31. Hu N, Xie S, Liu L, Wang X, Pan X, Chen G, et al. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 2010 ; 39: 419-25.
32. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos,1999, 27,1350-9.
33. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, et al. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 1992; 43: 667-70.
34. Ishigami M, Tokui T, Komai T, Tsukahara K, Yamazaki M, Sugiyama Y. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharm Res 1995; 12: 1741 -5.
35. Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681-4.
36. Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, et al. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28: 2092-5.
37. Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS B iol 2009; 7: e1000229.
38. Isaac R, Boura-Halfon S, Gurevitch D, Shainskaya A, Levkovitz Y, Zick Y. Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancr eatic beta cells. J Biol Chem 2013; 288: 5682-93.
39. Hoffman JB, Kaplan JR, Kinkead B, Berga SL, Wilson ME. Metabolic and reproductive consequences of the serotonin transporter promoter poly morphism (5-HTTLPR) in adult female rhesus monkeys (Macaca mulatta). Endocrine 2007; 31: 202-11.
40. Jarrell H, Hoffman JB, Kaplan JR, Berga S, Kinkead B, Wilson ME. Polymorphisms in the s erotonin reuptake transporter gene modify the consequences of social status on metabolic health in female rhesus monkeys. Physiol Behav 2008; 93: 807-19.
41. Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007; 9: 1-24.
42. Gilles M, Wilke A, Kopf D, Nonell A, Lehner t H, Deuschle M. Antagonism of the serotonin (5-HT)-2 re ceptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom Med 2005; 67: 748-51.
43. Zhang Q, Zhu Y, Zhou W, Gao L, Yuan L, Han X. Serotonin receptor 2C and insulin secretion. PLoS One 2013; 8: e54250.
44. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transportin g polypeptide, oatp2. Pharm Res 1999; 16: 904-8.
45. Hasegawa Y, Kishimoto S, Shibatani N, Inotsume N, Takeuchi Y, Fukushima S. The disposition of pravastatin in a rat model of streptozoto cin-induced diabetes and organic anion transporting polypeptide 2 and multidrug resistance-associated protein 2 expression in the liver. Biol Pharm Bull 2010; 33: 153-6.
46. Ellis LC, Hawksworth GM, Weave r RJ. ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol Appl Pharmacol 2013; 269: 187-94.
47. Kivisto KT, Grisk O, Hofmann U, Meissner K, Moritz KU, Ritter C, et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TRrats. Drug Metab Dispos 2005; 33: 1593-6.
48. Reynolds WA, Chez RA, Bhuyan BK, Neil GL. Placental transfer of streptozotocin in the rhesus monkey. Diabetes 1974; 23: 777-82.